新型硫化氢前药SG-1002在猪急性肢体缺血模型中的作用
在17只雌性小型猪中通过血管内闭塞髂外动脉诱导急性肢体缺血,随机给予安慰剂或SG-1002(800 mg口服,每日两次)35天;SG-1002升高循环硫化氢、硫烷硫和亚硝酸盐,增加缺血肢体血管数目并保留毛细血管密度,同时改善冠状动脉内皮依赖性舒张。
要点
- SG-1002升高循环硫化氢、硫烷硫和亚硝酸盐水平。
- SG-1002增加缺血肢体血管数目并保留毛细血管密度。
- SG-1002改善急性肢体缺血猪的冠状动脉内皮依赖性舒张。
核心结论
- 每日给予硫化氢前药SG-1002可升高循环硫化氢和一氧化氮信号,并保留缺血肢体的血管数目和密度。
- SG-1002在急性肢体缺血背景下改善冠状动脉内皮依赖性舒张,对冠状动脉血管床有保护效应。
研究设计与样本
- 研究在17只雌性小型猪中通过血管内闭塞髂外动脉诱导急性肢体缺血。
- 诱导后第7天将17只小型猪随机分配至安慰剂组或SG-1002组(800 mg口服,每日两次),治疗35天。
主要发现
- 第35天,SG-1002组循环硫化氢为5.0 ± 1.2 μmol/L,安慰剂组为1.8 ± 0.50 μmol/L(P < .05)。
- 第35天,SG-1002组硫烷硫为10.6 ± 2.3 μmol/L,安慰剂组为2.6 ± 0.8 μmol/L(P < .05)。
- 第35天,SG-1002组亚硝酸盐为0.5 ± 0.05 μmol/L,安慰剂组为0.3 ± 0.03 μmol/L(P < .005)。
- SG-1002组缺血肢体血管数目的血管造影评分为27.6 ± 1.6,安慰剂组为22.2 ± 1.8(P < .05)。
- SG-1002组缺血肢体毛细血管密度为128.3 ± 18.7 capillaries/mm2,安慰剂组为79.0 ± 9.8 capillaries/mm2(P < .05)。
临床怎么用
- 在急性肢体缺血动物模型中,SG-1002与循环硫化氢和一氧化氮信号升高相关,并保留缺血肢体血管结构。
- SG-1002在急性肢体缺血模型中还改善冠状动脉内皮依赖性舒张,提示可能具有全身血管保护效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Previous studies have shown that hydrogen sulfide (H2S) exerts potent proangiogenic properties under in vitro conditions and in rodent models. We sought to determine whether a novel H2S prodrug promotes peripheral revascularization in a swine model of acute limb ischemia (ALI). METHODS: ALI was induced in 17 female miniswine via intravascular occlusion of the external iliac. At day 7 after ALI induction, miniswine (n = 17) were randomized to received placebo or the H2S prodrug, SG-1002 (800 mg per os twice a day), for 35 days. At day 35 SG-1002 increased circulating levels of H2S (5.0 ± 1.2 μmol/L vs 1.8 ± 0.50 μmol/L; P < .05), sulfane sulfur (10.6 ± 2.3 μmol/L vs 2.6 ± 0.8 μmol/L; P < .05), and nitrite (0.5 ± 0.05 μmol/L vs 0.3 ± 0.03 μmol/L; P < .005) compared with placebo. SG-1002 therapy increased angiographic scoring in ischemic limb vessel number (27.6 ± 1.6 vs 22.2 ± 1.8; P < .05) compared with placebo. Treatment with SG-1002 preserved existing capillaries in ischemic limbs (128.3 ± 18.7 capillaries/mm2 vs 79.0 ± 9.8 capillaries/mm2; P < .05) compared with placebo. Interestingly, treatment with SG-1002 also improved coronary vasorelaxation responses to bradykinin and substance P in miniswine with ALI. CONCLUSIONS: Our results suggest that daily administration of the H2S prodrug, SG-1002, leads to an increase in circulating H2S and nitric oxide signaling and preserves vessel number and density in ischemic limbs. Furthermore, SG-1002 therapy improved endothelial-dependent coronary artery vasorelaxation in the setting of ALI. Our data demonstrate that SG-1002 preserves the vascular architecture in ischemic limbs and exerts vascular protective effects in the coronary vasculature in a model of peripheral vascular disease.
引用
- Rushing AM, Donnarumma E, Polhemus DJ, et al. Effects of a novel hydrogen sulfide prodrug in a porcine model of acute limb ischemia. J Vasc Surg. 2019. PMID: 30777693. doi:10.1016/j.jvs.2018.08.172
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。